toxylact: a02bb02 enprostil

The first professional lActological database in the word

Enprostil (ATC A02BB02) is a synthetic prostaglandin E2 analogue used as an antiulcer and gastric antisecretory agent, but it is contraindicated in pregnancy and considered incompatible with breastfeeding due to significant maternal toxicity and lack of safety data in infants.

ATC group and representatives

A02BB02 belongs to the subgroup of prostaglandins used for peptic ulcer disease and gastro‑oesophageal reflux under “Drugs for acid related disorders”.
Within this ATC code, enprostil is the sole active substance and is classified as an oral prostaglandin E2 (PGE2) analogue with antisecretory and cytoprotective properties.

Mechanism of action

Enprostil is a structural analogue of PGE2 that primarily activates EP3 receptors on gastric parietal cells, leading to inhibition of adenylate cyclase and reduced cAMP, which decreases proton pump activity and gastric acid secretion.
It additionally enhances mucosal protection by stimulating mucus and bicarbonate secretion, improving gastric mucosal blood flow, and exerting cytoprotective and anti‑inflammatory effects on the gastrointestinal mucosa.

Therapeutic indications and dosing

Clinically, enprostil has been evaluated for the treatment of duodenal and gastric ulcers, producing ulcer healing rates broadly comparable to standard H2‑receptor antagonists at typical doses such as 35 micrograms twice daily.
It is used orally as an antisecretory and antiulcer agent, but its use is now limited or withdrawn in many markets, reflecting the availability of safer and more effective alternatives.

Pharmacokinetics

Enprostil is administered orally and exerts a long‑lasting antisecretory effect, with single doses suppressing gastric acid secretion by up to about 80% for nearly 12 hours in pharmacological studies.
It is a lipophilic prostaglandin derivative with systemic absorption and distribution consistent with other PGE2 analogues, but detailed modern population pharmacokinetic data, including protein binding and elimination pathways, remain limited in the public domain.

General toxicology

In clinical studies, the most frequent adverse effects are gastrointestinal, including abdominal cramping, flatulence, nausea, and especially diarrhoea, which reflects its prostaglandin‑mediated stimulation of intestinal motility.
High doses or increased sensitivity can lead to profuse hypermotility diarrhoea and associated fluid and electrolyte loss; in animal data cited locally, LD50 in primates is approximately 0.32 mg/kg, with severe toxicity described as altered mental status progressing to coma, tremor, and central cyanosis.

Reproductive toxicity and pregnancy

Enprostil, as a potent prostaglandin E2 analogue, carries a substantial risk of uterotonic and abortifacient effects and is therefore absolutely contraindicated in pregnancy.
The local monograph classifies the toxicological risk in pregnancy as FDA category X, reflecting evidence or high theoretical risk of fetal harm where the risks clearly outweigh any potential therapeutic benefit.

Lactation pharmacology

Based on its physicochemical properties as a lipophilic prostaglandin analogue and local data, the plasma:milk ratio for enprostil is estimated around 1:1, indicating similar concentrations in maternal plasma and breast milk.
No controlled pharmacokinetic studies in lactating women or breastfed infants were identified, and there are no published case reports of infant exposure via breast milk, leaving the actual infant dose and clinical effects essentially unknown.

Lactation safety and risk assessment

The local toxicology‑lactology source categorizes enprostil as “toxico‑lactation category IV – incompatible with breastfeeding,” reflecting the combination of significant maternal toxicity, theoretical prostaglandin‑mediated effects in the infant, and lack of safety data.
Given its equal plasma:milk distribution, potential for gastrointestinal and systemic effects, and the availability of alternative antiulcer therapies with established lactation safety profiles, enprostil should be avoided during breastfeeding and considered contraindicated in nursing mothers.

Clinical recommendations in breastfeeding

If a breastfeeding woman requires treatment for peptic ulcer or acid‑related disease, other agents with better‑documented safety in lactation (such as H2‑receptor antagonists or proton pump inhibitors) should be preferred instead of enprostil.
If enprostil exposure occurs inadvertently in a lactating woman, temporary interruption of breastfeeding with provision of previously expressed milk or formula is advisable, while monitoring the mother for gastrointestinal and neurological adverse effects and the infant for diarrhoea, irritability, or lethargy.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.